Overview

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Phase:
Phase 3
Details
Lead Sponsor:
Kodiak Sciences Inc